Remote management of osteoporosis in the first wave of the COVID-19 pandemic

[11] Ivergård M(2020)Endocrinology in the time of COVID-19: management of hyperthyroidism and hypothyroidism Eur J Endocrinol 183 G57-G65

[12] Biarnés-Suñé A(2020)Endocrinology in the time of COVID-19: management of pituitary tumours Eur J Endocrinol 42 52-62

[13] Solà-Enríquez B(2020)Endocrinology in the time of COVID-19: management of diabetes insipidus and hyponatraemia Eur J Endocrinol 102 607-618

[14] González Posada MÁ(2020)Management of calcium metabolic disorders and osteoporosis Eur J Endocrinol 102 501-502

[15] Pluskiewicz W(2012)Skeletal and extraskeletal actions of denosumab Endocrine 56 138-826

[16] Wilk R(2018)Osteoporosis in rheumatic diseases: anti-rheumatic drugs and the skeleton Calcif Tissue Int 40 825-205

[17] Adamczyk P(2018)Osteoimmunology Calcif Tissue Int 70 203-97

[18] Ojeda-Thies C(2020)Alarmins in osteoporosis, RAGE, IL-1, and IL-33 pathways: a literature review Medicina (B Aires) 85 78-624

[19] Cuarental-García J(2020)Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs Rheumatol Int 70 617-346

[20] Ramos-Pascua LR(2020)Are women with osteoporosis treated with denosumab at risk of severe COVID-19? Endocrine 18 335-13

[11] Ivergård M(2020)Endocrinology in the time of COVID-19: management of hyperthyroidism and hypothyroidism Eur J Endocrinol 183 G57-G65

[12] Biarnés-Suñé A(2020)Endocrinology in the time of COVID-19: management of pituitary tumours Eur J Endocrinol 42 52-62

[13] Solà-Enríquez B(2020)Endocrinology in the time of COVID-19: management of diabetes insipidus and hyponatraemia Eur J Endocrinol 102 607-618

[14] González Posada MÁ(2020)Management of calcium metabolic disorders and osteoporosis Eur J Endocrinol 102 501-502

[15] Pluskiewicz W(2012)Skeletal and extraskeletal actions of denosumab Endocrine 56 138-826

[16] Wilk R(2018)Osteoporosis in rheumatic diseases: anti-rheumatic drugs and the skeleton Calcif Tissue Int 40 825-205

[17] Adamczyk P(2018)Osteoimmunology Calcif Tissue Int 70 203-97

[18] Ojeda-Thies C(2020)Alarmins in osteoporosis, RAGE, IL-1, and IL-33 pathways: a literature review Medicina (B Aires) 85 78-624

[19] Cuarental-García J(2020)Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs Rheumatol Int 70 617-346

[20] Ramos-Pascua LR(2020)Are women with osteoporosis treated with denosumab at risk of severe COVID-19? Endocrine 18 335-13